Growth Metrics

Travere Therapeutics (TVTX) Non-Current Deferred Tax Liability (2016 - 2017)

Historic Non-Current Deferred Tax Liability for Travere Therapeutics (TVTX) over the last 5 years, with Q4 2017 value amounting to $16.8 million.

  • Travere Therapeutics' Non-Current Deferred Tax Liability fell 6548.25% to $16.8 million in Q4 2017 from the same period last year, while for Dec 2017 it was $16.8 million, marking a year-over-year decrease of 6548.25%. This contributed to the annual value of $16.8 million for FY2017, which is 6548.25% down from last year.
  • Per Travere Therapeutics' latest filing, its Non-Current Deferred Tax Liability stood at $16.8 million for Q4 2017, which was down 6548.25% from $1.2 million recorded in Q2 2017.
  • Over the past 5 years, Travere Therapeutics' Non-Current Deferred Tax Liability peaked at $48.7 million during Q4 2016, and registered a low of $141000.0 during Q4 2014.
  • For the 5-year period, Travere Therapeutics' Non-Current Deferred Tax Liability averaged around $14.6 million, with its median value being $12.1 million (2016).
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first plummeted by 9457.88% in 2014, then soared by 1715390.07% in 2015.
  • Quarter analysis of 5 years shows Travere Therapeutics' Non-Current Deferred Tax Liability stood at $2.6 million in 2013, then tumbled by 94.58% to $141000.0 in 2014, then surged by 17153.9% to $24.3 million in 2015, then skyrocketed by 100.18% to $48.7 million in 2016, then tumbled by 65.48% to $16.8 million in 2017.
  • Its Non-Current Deferred Tax Liability was $16.8 million in Q4 2017, compared to $1.2 million in Q2 2017 and $4.4 million in Q1 2017.